DE69928064T2 - Mimotopen der hypervariabelen region 1 des e2 glykoproteins von hcv und deren verwendungen - Google Patents

Mimotopen der hypervariabelen region 1 des e2 glykoproteins von hcv und deren verwendungen Download PDF

Info

Publication number
DE69928064T2
DE69928064T2 DE69928064T DE69928064T DE69928064T2 DE 69928064 T2 DE69928064 T2 DE 69928064T2 DE 69928064 T DE69928064 T DE 69928064T DE 69928064 T DE69928064 T DE 69928064T DE 69928064 T2 DE69928064 T2 DE 69928064T2
Authority
DE
Germany
Prior art keywords
peptides
peptide
composition
hcv
hvr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928064T
Other languages
German (de)
English (en)
Other versions
DE69928064D1 (de
Inventor
Alfredo Nicosia
Armin Lahm
Anna Tramontano
Riccardo Cortese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Application granted granted Critical
Publication of DE69928064D1 publication Critical patent/DE69928064D1/de
Publication of DE69928064T2 publication Critical patent/DE69928064T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69928064T 1998-05-19 1999-05-14 Mimotopen der hypervariabelen region 1 des e2 glykoproteins von hcv und deren verwendungen Expired - Lifetime DE69928064T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9810756.8A GB9810756D0 (en) 1998-05-19 1998-05-19 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
GB9810756 1998-05-19
PCT/EP1999/003344 WO1999060132A1 (en) 1998-05-19 1999-05-14 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Publications (2)

Publication Number Publication Date
DE69928064D1 DE69928064D1 (de) 2005-12-08
DE69928064T2 true DE69928064T2 (de) 2006-07-20

Family

ID=10832337

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928064T Expired - Lifetime DE69928064T2 (de) 1998-05-19 1999-05-14 Mimotopen der hypervariabelen region 1 des e2 glykoproteins von hcv und deren verwendungen

Country Status (13)

Country Link
US (1) US7034108B1 (enExample)
EP (1) EP1002092B1 (enExample)
JP (1) JP4593780B2 (enExample)
KR (1) KR20010022026A (enExample)
CN (1) CN1274387A (enExample)
AT (1) ATE308618T1 (enExample)
AU (1) AU766610B2 (enExample)
CA (1) CA2297408C (enExample)
DE (1) DE69928064T2 (enExample)
DK (1) DK1002092T3 (enExample)
ES (1) ES2251832T3 (enExample)
GB (1) GB9810756D0 (enExample)
WO (1) WO1999060132A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
EP1290230A4 (en) * 2000-06-02 2004-10-20 Merck & Co Inc HEPATITIS C VIRUS CONJUGATE
WO2002045743A2 (en) * 2000-12-09 2002-06-13 Cambridge University Technical Services Limited Hcv vaccines
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
EP2172552A3 (en) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
CN1305898C (zh) * 2003-08-22 2007-03-21 中国科学院上海生命科学研究院 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
JP5031827B2 (ja) * 2006-06-01 2012-09-26 程云 予防或いは肝損傷を治療するペプチッド
WO2007146975A2 (en) * 2006-06-13 2007-12-21 Athenix Corporation Methods for generating genetic diversity by permutational mutagenesis
BRPI0719672A2 (pt) 2006-11-29 2013-12-24 Athenix Corp Molécula isolada de ácido nucleico, vetor, célula hospedeira, planta transgênica, semente transgênica, polipeptídeo isolado, método para produzir um polipeptídeo com atividade de resistência a herbicidas, método para conferir resistência a um herbicida em uma planta, planta, método para aumentar o vigor ou rendimento de uma planta, método para conferir resistência ao glifosato a uma planta
CN110078800B (zh) * 2019-04-24 2021-01-29 中国人民解放军第二军医大学 合成肽在制备防治肝炎病毒感染药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
JPH11124398A (ja) * 1997-10-22 1999-05-11 Japan Energy Corp Ｃ型肝炎ウイルス由来の抗原ペプチドとそれを用いる抗体検査薬

Also Published As

Publication number Publication date
JP4593780B2 (ja) 2010-12-08
CA2297408A1 (en) 1999-11-25
CA2297408C (en) 2011-06-21
EP1002092B1 (en) 2005-11-02
KR20010022026A (ko) 2001-03-15
ES2251832T3 (es) 2006-05-01
DK1002092T3 (da) 2006-03-06
AU766610B2 (en) 2003-10-16
CN1274387A (zh) 2000-11-22
GB9810756D0 (en) 1998-07-15
WO1999060132A1 (en) 1999-11-25
DE69928064D1 (de) 2005-12-08
AU4143599A (en) 1999-12-06
ATE308618T1 (de) 2005-11-15
EP1002092A1 (en) 2000-05-24
JP2002515249A (ja) 2002-05-28
US7034108B1 (en) 2006-04-25

Similar Documents

Publication Publication Date Title
AT400724B (de) Virales polypeptid
US6372884B1 (en) Biologically active compounds and methods of constructing and using the same
DE69922958T3 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE69232871T2 (de) Polypeptide des hepatitis c-virus (hiv)
DE69413024T2 (de) Verfahren zur herstellung von immunogenen oder diagnostischen reagentien und ebensolche
DE69033425T2 (de) HCV-Isolat J-1
DE69328489T2 (de) Stress-proteine epitopen
US7521177B2 (en) Flavivirus detection methods employing recombinant antigens comprising a Japanese encephalitis (JEV) signal sequence
DE69526665T2 (de) Antigen bindende peptide (abtides) aus peptidbibliotheken
DE60125751T2 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
DE69018142T2 (de) Stressproteine aus Pilzen.
DE69434117T3 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
DE60129278T2 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE69635843T2 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
DE69928064T2 (de) Mimotopen der hypervariabelen region 1 des e2 glykoproteins von hcv und deren verwendungen
DE69535360T2 (de) Synthetische peptide und impfstoffe welche diese beinhalten
DE69934583T2 (de) Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
DE69938451T2 (de) Fas peptide und antikörper zur modulierung von apoptosis
DE3855471T2 (de) Oligopeptide und ihre Anwendung zu Diagnose- und Impfzwecken für AIDS und ARC
JPS59500216A (ja) ヘルペス・シンプレツクスウイルスのワクチン接種の材料および方法
DE69433160T2 (de) Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
DE69931518T2 (de) Chimäres Gen, das für die antigenischen Determinaten von vier Proteinen aus L. Infantum kodiert
JP2007515394A (ja) ドメイン交換結合分子、その使用方法および製造方法
DE3485974T3 (de) Molekularkloniertes diagnostisches Produkt und Verfahren zur Verwendung.
DE69839242T2 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition